RxDoctor Payments Data

Christine Gavino, DO

Family Medicine · Magnolia, TXNPI 1558709881

Payments from drug & device makers

$4,030in general payments, 2019–2025

Across 227 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$616
  • Pfizer$502
  • Abbott$330
  • Novo Nordisk$266
  • Boehringer Ingelheim$260
  • Exact Sciences$251
  • plus $2K from 38 others

What the payments were for

  • Food & beverage$4,030100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,030 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$77,670
Medicare patients
176
Services billed
1,319

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide49$50,298
EliquisApixaban30$40,593
OzempicSemaglutide26$31,829
JardianceEmpagliflozin14$16,362
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$13,065
LinzessLinaclotide12$10,533
XareltoRivaroxaban12$6,589
Levothyroxine Sodium210$2,610
Atorvastatin Calcium164$1,740
Azelastine Hcl39$1,522
Estradiol40$1,516
Celecoxib45$1,486
SynthroidLevothyroxine Sodium30$1,411
Rosuvastatin Calcium117$1,394
Pregabalin32$1,220

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$616$50,29849 claims
PfizerEliquis$502$40,59330 claims
Novo NordiskOzempic$266$31,82926 claims
Boehringer IngelheimJardiance$260$16,36214 claims
GSKTrelegy Ellipta$100$13,06512 claims
AbbVieLinzess, Synthroid$127$11,94442 claims
Johnson & JohnsonXarelto$146$6,58912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Magnolia

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →